PACT WITH THE DEVIL: ALEMTUZUMAB THERAPY, IMMUNE SUPPRESSION AND INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Authors

  • I. ANTOHE University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • Angela DASCALESCU University of Medicine and Pharmacy “Grigore T. Popa”- Iasi
  • Cristina BURCOVEANU Regional Oncology Institute Iasi
  • Doramina GHIORGHIU Regional Oncology Institute Iasi
  • Alina DASCALU Regional Oncology Institute Iasi
  • C. DANAILA University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

Keywords:

CHRONIC LYMPHOCYTIC LEUKEMIA, ALEMTUZUMAB, IMMUNE SUPPRESSION, MYCOBACTERIUM TUBERCULOSIS, ATYPICAL INFECTION.

Abstract

Infectious complications are an important cause of hospitalization in patients diagnosed with chronic lymphocytic leukemia. The pathogenesis of infection is complex, involving both disease-induced and treatment-related immune depression. During the last decade, the management of chronic lymphocytic leukemia (CLL) has been redefined by the approval of monoclonal antibody-based treatment, which resulted in improved therapeutic responses. Nonetheless, the profound lymphopenia induced by monoclonal agents was accompanied by increased incidence of infections caused by a new spectrum of opportunistic microorganisms. We report the case of a patient with hypercellular CLL who received Alemtuzumab as first line therapy and obtained a satisfactory therapeutic response, but developed subsequent atypical infectious complications.

Author Biographies

  • I. ANTOHE, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Ph.D. Student

  • Angela DASCALESCU, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Discipline of Hematology

  • Cristina BURCOVEANU, Regional Oncology Institute Iasi


  • C. DANAILA, University of Medicine and Pharmacy “Grigore T. Popa”- Iasi

    Faculty of Medicine
    Discipline of Hematology

References

1. Molica S. Infections in chronic lymphocytic leukemia: risk factors and impact on survival and treatment. Leuk Lymphoma 1994; 13: 203-214.
2. Wadhwa P, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 240-249.
3. Ravandi F, O’Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197-209.
4. Hallek M. Chronic lymphocytic leukemia for the clinician. Annals of Oncology 2011; 22 (Supplement 4): iv54-iv56.
5. Salvana EMT, Robert AS. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009; 22: 274-290.
6. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Cl Ha 2010; 23: 85-96.
7. Morrison AV. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Cl Ha 2010; 23: 145-153.
8. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013; 121 (14): 2704-2714.
9. Ysebaert L. T cells in CLL: lost in migration. Blood 2013; 121 (14): 2580-2582.
10. Kontoyiannis DP, Georgiadou SP, Wierda WG et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54 (8): doi:10.3109/10428194.2012.750723.
11. Nosari A. Infectious Complications in Chronic Lymphocytic Leukemia. Mediterr J Hematol Infect Dis 2012; 4 (1): doi:10.4084/MJHID.2012.070.

Additional Files

Published

2018-05-14

Issue

Section

INTERNAL MEDICINE - PEDIATRICS